AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

TELIX PHARMACEUTICALS LTD

26.800

+0.1800.68%

Volume:1.11M

Turnover:29.80M

Market Cap:9.06B

PE:185.34

High:27.170

Open:26.880

Low:26.360

Close:26.620

Loading ...

Overview Company News Filings

Telix Pharmaceuticals Says US FDA Approves New Drug Application for Prostate Cancer Imaging Agent

MT Newswires Live

Telix shares slip 11% from highs. Time to buy this high flying biotech?

ASX Alert-FDA Approves New Prostate Cancer Imaging Agent Gozellix-Tlx.ax

THOMSON REUTERS

Telix Pharmaceuticals' Illuccix Approved in Brazil for Prostate Cancer Imaging; Forms Joint Venture With R2PHARMA

MT Newswires Live

BRIEF-Telix Pharmaceuticals Says Illuccix Approved For Prostate Cancer Imaging In Brazil

Telix Pharmaceuticals Says Prostate Cancer Imaging Agent Approved in Brazil

MT Newswires Live

Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America

Telix Pharmaceuticals Ltd - Illuccix Approved for Prostate Cancer Imaging in Brazil

THOMSON REUTERS

Telix Develops, Validates Generator Technology to Produce Lead Isotype

MT Newswires Live

Telix Pharmaceuticals Adds Isotope Production Capability

MT Newswires Live

BRIEF-Telix Pharmaceuticals Completes Fap-Targeting Theranostic Acquisition

Up 136% in a year, why is this ASX 200 share slipping on Wednesday?

Telix Completes Acquisition of Pan-Cancer Targeting Assets

MT Newswires Live

Telix Pharmaceuticals Ltd - at Closing, Telix Paid EUR 5.3 Mln in Cash

THOMSON REUTERS

ASX Alert-Telix Completes Fap-Targeting Theranostic Acquisition-Tlx.ax

THOMSON REUTERS

DIARY-Australia, New Zealand corporate earnings week ahead

Grand Pharmaceutical Group Divests 45% of Telix Pharmaceuticals Shares

MT Newswires Live

BRIEF-Grand Pharmaceutical Provides Update On Strategic Investment In Telix

Guess which ASX 200 company co-founders just sold $118 million in shares

Why Brainchip, Endeavour, Star, and Telix shares are sinking today

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/TLX.AU/news?page=5"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"TLX.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","market":"AU","secType":"STK","nameCN":"TELIX PHARMACEUTICALS LTD","latestPrice":26.8,"timestamp":1746771120000,"preClose":26.62,"halted":0,"volume":1111086,"delay":0,"nameEN":"TELIX PHARMACEUTICALS LTD","floatShares":274906865,"shares":337878497,"eps":0.1446,"marketStatus":"Market Closed","change":0.18,"latestTime":"05-09 16:12:00 AEST","open":26.88,"high":27.17,"low":26.36,"amount":29801371,"amplitude":0.030428,"askPrice":26.83,"askSize":8954,"bidPrice":26.76,"bidSize":1500,"shortable":3,"etf":0,"ttmEps":0.1446,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1747008000000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":26.62,"openAndCloseTimeList":[[1746748800000,1746770400000]],"volumeRatio":0.6589934372030005,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"TLX.AU\",,,,,undefined,":{"symbol":"TLX.AU","floatShares":274906865,"roa":"5.33%","roe":"13.92%","lyrEps":0.150709,"volumeRatio":0.6589934372030005,"shares":337878497,"dividePrice":0,"high":27.17,"amplitude":0.030428,"preClose":26.62,"low":26.36,"week52Low":14.42,"pbRate":"15.94","psRate":"11.56","week52High":31.97,"institutionHeld":0,"latestPrice":26.8,"committee":-0.713029,"eps":0.1446,"divideRate":0,"volume":1111086,"delay":0,"ttmEps":0.1446,"open":26.88,"prevYearClose":24.61,"prevWeekClose":29.32,"prevMonthClose":27.13,"prevQuarterClose":26.52,"fiveDayClose":29.32,"twentyDayClose":24.81,"sixtyDayClose":27.75},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"TLX.AU\",pageSize:20,pageCount:5,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2521159416","title":"Telix Pharmaceuticals Says US FDA Approves New Drug Application for Prostate Cancer Imaging Agent","url":"https://stock-news.laohu8.com/highlight/detail?id=2521159416","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521159416?lang=en_us&edition=fundamental","pubTime":"2025-03-21 08:15","pubTimestamp":1742516111,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  said that the US Food and Drug Administration has approved its New Drug Application for Gozellix, the company's prostate-specific membrane antigen positron emission tomography  imaging agent for prostate cancer, according to a Friday filing with the Australian bourse.Gozellix is designed for PET scanning of PSMA-positive lesions in men with prostate cancer, the filing said.The agent offers a six-hour shelf life and extended distribution range compared to existing gallium-based imaging agents, improving access to PET scanners which currently cannot use other PSMA imaging products, filing added.Telix expects Gozellix to expand access by qualifying for full reimbursement with reduced or no patient co-insurance, which will benefit underserved populations.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX","BK7067","TLX.AU"],"gpt_icon":0},{"id":"2521419556","title":"Telix shares slip 11% from highs. Time to buy this high flying biotech?","url":"https://stock-news.laohu8.com/highlight/detail?id=2521419556","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521419556?lang=en_us&edition=fundamental","pubTime":"2025-03-21 06:59","pubTimestamp":1742511540,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals Ltd shares have slipped by around 11% from their former highs of $31 apiece since last February.  This isn't a Telix–only issue. The S&P/ASX 200 Index  is also down 5% this past month. This comes as global equity markets took a major hit at end of February. As for Telix, the biotech stock closed the session at $27.80 apiece on Thursday. Is this latest dip a buying opportunity?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/03/21/telix-shares-slip-11-from-highs-time-to-buy-this-high-flying-biotech/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BLA.AU","XJO.AU","TLX.AU","BK7067"],"gpt_icon":0},{"id":"2521492862","title":"ASX Alert-FDA Approves New Prostate Cancer Imaging Agent Gozellix-Tlx.ax","url":"https://stock-news.laohu8.com/highlight/detail?id=2521492862","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521492862?lang=en_us&edition=fundamental","pubTime":"2025-03-21 05:24","pubTimestamp":1742505896,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250320:nFWN3Q30RA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","TLX.AU"],"gpt_icon":0},{"id":"2520244096","title":"Telix Pharmaceuticals' Illuccix Approved in Brazil for Prostate Cancer Imaging; Forms Joint Venture With R2PHARMA","url":"https://stock-news.laohu8.com/highlight/detail?id=2520244096","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520244096?lang=en_us&edition=fundamental","pubTime":"2025-03-18 19:46","pubTimestamp":1742298364,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  said late Monday that the Brazilian Health Regulatory Agency has approved the company's prostate cancer imaging agent, Illuccix.The company said the approval was granted to Telix's partner, R2PHARMA, and a subsidiary of Grupo GSH, which has been given an exclusive license to manufacture, distribute and market Illuccix in Brazil.Telix sadi it has formed a joint venture with R2PHARMA, named Telix Innovations Brazil, to commercialize and distribute Illuccix and other products from its pipeline in Brazil.Illuccix is already available in several countries, including Australia, Canada, New Zealand, the US, the UK, and various nations in the European Economic Area.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK4139","TLX.AU","TLX","JYNT","BK4185"],"gpt_icon":0},{"id":"2520632741","title":"BRIEF-Telix Pharmaceuticals Says Illuccix Approved For Prostate Cancer Imaging In Brazil","url":"https://stock-news.laohu8.com/highlight/detail?id=2520632741","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520632741?lang=en_us&edition=fundamental","pubTime":"2025-03-18 09:22","pubTimestamp":1742260940,"startTime":"0","endTime":"0","summary":"BRIEF-Telix Pharmaceuticals Says Illuccix Approved For Prostate Cancer Imaging In BrazilMarch 18 (Reuters) - Telix Pharmaceuticals Ltd TLX.AX:ILLUCCIX APPROVED FOR PROSTATE CANCER IMAGING IN BRAZILFurther company coverage: TLX.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250318:nFWN3Q00RI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"gpt_icon":0},{"id":"2520638074","title":"Telix Pharmaceuticals Says Prostate Cancer Imaging Agent Approved in Brazil","url":"https://stock-news.laohu8.com/highlight/detail?id=2520638074","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520638074?lang=en_us&edition=fundamental","pubTime":"2025-03-18 07:32","pubTimestamp":1742254371,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) said the Brazilian Health Regulatory Agency approved its prostate cancer imaging agent Illuccix, according to a Tuesday Australian bourse filing.The marketing authoriza","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK6117","BK7067","XJO.AU","TLX","TLX.AU","XKO.AU","BK4139","XAO.AU","BK6505","BDX.SI"],"gpt_icon":0},{"id":"2520842426","title":"Illuccix® Approved for Prostate Cancer Imaging in Brazil: First Marketing Authorization in Latin America","url":"https://stock-news.laohu8.com/highlight/detail?id=2520842426","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520842426?lang=en_us&edition=fundamental","pubTime":"2025-03-18 05:53","pubTimestamp":1742248380,"startTime":"0","endTime":"0","summary":"MELBOURNE,Australia andPORTO ALEGRE,Brazil, March 18, 2025  -- Telix Pharmaceuticals Limited  today announces that the Brazilian Health Regulatory Agency  has approved Illuccix  the Company’s lead prostate cancer imaging agent. Illuccix is the first and only PSMA-PET1 prostate cancer imaging agent to receive full regulatory approval in Brazil.Illuccix, after radiolabeling with 68Ga, is a radioactive diagnostic agent indicated for positron emission tomography  of prostate-specific membrane antigen  positive lesions in men with prostate cancer:. With suspected metastasis who are candidates for definitive initial therapy treatment, and. With suspected recurrence based on an elevated specific antigen  level in the serum.PSMA-PET is a diagnostic technology demonstrated to detect advanced prostate cancer. ANVISA becomes the latest regulatory body worldwide to approve Illuccix3, which is already commercially available in Australia, Canada, New Zealand and the United States, and has recently b","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/illuccix-approved-prostate-cancer-imaging-215300352.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["BK7039","ASX","TGA","XKO.AU","EEA","BK7047","BK7067","BK7001","TLX","BK4233","SEC.AU","BK4585","BK4192","BK4213","PET","TGA.AU","TLX.AU","BK4084","BK4144","BK4141","PET.AU","DCP","XJO.AU","BK4533","BK4217","BK4588","BK4543","BK4139","BK4526","XAO.AU","UK","BK4528","BK4205","PSA","ASX.AU"],"gpt_icon":0},{"id":"2520681975","title":"Telix Pharmaceuticals Ltd - Illuccix Approved for Prostate Cancer Imaging in Brazil","url":"https://stock-news.laohu8.com/highlight/detail?id=2520681975","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520681975?lang=en_us&edition=fundamental","pubTime":"2025-03-18 05:30","pubTimestamp":1742247045,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250317:nFWN3Q00RI:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","TLX.AU"],"gpt_icon":0},{"id":"2519897643","title":"Telix Develops, Validates Generator Technology to Produce Lead Isotype","url":"https://stock-news.laohu8.com/highlight/detail?id=2519897643","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519897643?lang=en_us&edition=fundamental","pubTime":"2025-03-14 09:14","pubTimestamp":1741914857,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals  developed and validated a generator technology to produce the lead-212 isotope for Targeted Alpha Therapy, completing its first production run, according to a Thursday statement.The technology, created by Telix's IsoTherapeutics team, uses a sealed thorium-228 source, offering higher radioactivity, improved yield, and longer shelf life than the existing technology, overcoming lead-212 short half-life and production challenges, the statement said.The automated generator produces up to 60 clinical doses per elution and can be scaled for broader production, the statement added.Telix plans to expand this technology across its manufacturing and distribution networks, including the recently acquired RLS Radiopharmacies, the company said.Shares of the company rose 1% in recent Friday trade.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX.AU","BK7067"],"gpt_icon":0},{"id":"2519004638","title":"Telix Pharmaceuticals Adds Isotope Production Capability","url":"https://stock-news.laohu8.com/highlight/detail?id=2519004638","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519004638?lang=en_us&edition=fundamental","pubTime":"2025-03-13 16:23","pubTimestamp":1741854229,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (TLX) said late Wednesday it completed the first production of lead-212 isotope using a new generator technology.The technology \"significantly\" increases the amount of radioactiv","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["TLX","BK7067","TLX.AU","BK4139"],"gpt_icon":0},{"id":"2518880670","title":"BRIEF-Telix Pharmaceuticals Completes Fap-Targeting Theranostic Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2518880670","media":"Reuters","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518880670?lang=en_us&edition=fundamental","pubTime":"2025-03-12 09:15","pubTimestamp":1741742130,"startTime":"0","endTime":"0","summary":"BRIEF-Telix Pharmaceuticals Completes Fap-Targeting Theranostic AcquisitionMarch 12  - Telix Pharmaceuticals TLX.AX:ASX ALERT-TELIX COMPLETES FAP-TARGETING THERANOSTIC ACQUISITION-TLX.AXAT CLOSING, TELIX PAID EUR 5.3 MILLION IN CASHFurther company coverage: TLX.AX ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250312:nFWN3PU17I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","TLX.AU"],"gpt_icon":0},{"id":"2518334210","title":"Up 136% in a year, why is this ASX 200 share slipping on Wednesday?","url":"https://stock-news.laohu8.com/highlight/detail?id=2518334210","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518334210?lang=en_us&edition=fundamental","pubTime":"2025-03-12 07:53","pubTimestamp":1741737203,"startTime":"0","endTime":"0","summary":"Commenting on the acquisition that could offer long-term support for the ASX 200 share, Telix CEO, Therapeutics, Richard Valeix, said:  We are pleased to have finalised this transaction so that we can continue to leverage the FAP-targeting research pioneered by Professor Rosch and his team. We believe this technology holds great promise for both imaging and treating tumours, and Telix is now focused on using these compounds to build out our urology franchise and explore pan-cancer opportunities, with the goal of bringing new theranostic solutions to physicians and their patients.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/03/12/up-136-in-a-year-why-is-this-asx-200-share-slipping-on-wednesday/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7067","TLX.AU","XJO.AU"],"gpt_icon":0},{"id":"2518225709","title":"Telix Completes Acquisition of Pan-Cancer Targeting Assets","url":"https://stock-news.laohu8.com/highlight/detail?id=2518225709","media":"MT Newswires Live","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518225709?lang=en_us&edition=fundamental","pubTime":"2025-03-12 07:30","pubTimestamp":1741735812,"startTime":"0","endTime":"0","summary":"Telix Pharmaceuticals (ASX:TLX) completed the acquisition of therapeutic and diagnostic radiopharmaceutical assets targeting fibroblast activation protein, a pan-cancer target, according to a Wednesda","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","TLX.AU"],"gpt_icon":0},{"id":"2518770788","title":"Telix Pharmaceuticals Ltd -  at Closing, Telix Paid EUR 5.3 Mln in Cash","url":"https://stock-news.laohu8.com/highlight/detail?id=2518770788","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518770788?lang=en_us&edition=fundamental","pubTime":"2025-03-12 05:30","pubTimestamp":1741728654,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250311:nFWN3PU17I:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["TLX.AU","BK7067"],"gpt_icon":0},{"id":"2518770271","title":"ASX Alert-Telix Completes Fap-Targeting Theranostic Acquisition-Tlx.ax","url":"https://stock-news.laohu8.com/highlight/detail?id=2518770271","media":"THOMSON REUTERS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2518770271?lang=en_us&edition=fundamental","pubTime":"2025-03-12 05:30","pubTimestamp":1741728654,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250311:nFWN3PU17I:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","TLX.AU"],"gpt_icon":0},{"id":"2517570143","title":"DIARY-Australia, New Zealand corporate earnings week ahead","url":"https://stock-news.laohu8.com/highlight/detail?id=2517570143","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2517570143?lang=en_us&edition=fundamental","pubTime":"2025-03-07 09:00","pubTimestamp":1741309200,"startTime":"0","endTime":"0","summary":"DIARY-Australia, New Zealand corporate earnings week aheadMarch 7(Reuters) - Diary of Australia and New Zealand (.AXJO, .NZ50) corporate earnings for the week ahead AUSTRALIA & NEW ZEALAND EARNINGS St","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250307:nL3N3PP1EY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["TLX.AU"],"gpt_icon":0},{"id":"2516673406","title":"Grand Pharmaceutical Group Divests 45% of Telix Pharmaceuticals Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2516673406","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516673406?lang=en_us&edition=fundamental","pubTime":"2025-03-04 20:40","pubTimestamp":1741092057,"startTime":"0","endTime":"0","summary":"Grand Pharmaceutical Group  sold about 45.2% of its stake in Telix Pharmaceuticals  for AU$143 million in an off-the-market transaction, a Friday Hong Kong bourse filing said.The group will use proceeds from the disposal to fund its clinical development plans in areas of unmet need, including projects under its partnership with Telix.Grand Pharmaceutical Group plans not to sell the remaining stake it holds in Telix in the coming 12 months.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["00512","BK7067","TLX.AU","BK1191","TLX"],"gpt_icon":0},{"id":"2514946341","title":"BRIEF-Grand Pharmaceutical Provides Update On Strategic Investment In Telix","url":"https://stock-news.laohu8.com/highlight/detail?id=2514946341","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514946341?lang=en_us&edition=fundamental","pubTime":"2025-02-28 18:24","pubTimestamp":1740738257,"startTime":"0","endTime":"0","summary":"BRIEF-Grand Pharmaceutical Provides Update On Strategic Investment In TelixFeb 28 (Reuters) - Grand Pharmaceutical Group Ltd 0512.HK:UPDATE ON STRATEGIC INVESTMENT IN TELIXDEAL FOR  AU$143 MILLION.DIS","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nFWN3PJ111:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["00512","BK7067","BK1191","TLX.AU"],"gpt_icon":0},{"id":"2514100396","title":"Guess which ASX 200 company co-founders just sold $118 million in shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2514100396","media":"MotleyFool","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514100396?lang=en_us&edition=fundamental","pubTime":"2025-02-28 12:46","pubTimestamp":1740717998,"startTime":"0","endTime":"0","summary":"ASX 200 healthcare share Telix Pharmaceuticals Ltd fell 9.4% to an intraday low of $27.52 as the market digested news of a $118 million off-market trade by the co-founders.The shares were sold for $29.50 apiece after the market close on Wednesday.ASX 200 healthcare share dips following block trade. Telix Pharmaceuticals shares closed at $31.05 on Wednesday.Hence, the block trade was executed at a 5% discount.The Australian Financial Review  reported that JPMorgan had been appointed to shop the four million shares around after the day's trading session finished on Wednesday.Dr Behrenbruch sold his shares as part of his divorce settlement and for estate planning purposes. The shares sold were held in a family trust.Dr Behrenbruch has committed not to sell any more Telix shares for the next 12 months.The company said the sale represented less than 10% of Dr Behrenbruch's holdings. Following the trade, he now holds 6.3% of Telix's issued capital.The Telix board approved the sale to occur w","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/02/28/guess-which-asx-200-company-co-founders-just-sold-118-million-in-shares/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["AFR.AU","TLX.AU","BK7067"],"gpt_icon":0},{"id":"2514220390","title":"Why Brainchip, Endeavour, Star, and Telix shares are sinking today","url":"https://stock-news.laohu8.com/highlight/detail?id=2514220390","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514220390?lang=en_us&edition=fundamental","pubTime":"2025-02-28 09:45","pubTimestamp":1740707110,"startTime":"0","endTime":"0","summary":"In afternoon trade, theS&P/ASX 200 Index (ASX: XJO) is on course to end the week deep in the red. At the time of writing, the benchmark index is down 0.75% to 8,205.8 points. Four ASX shares that are ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/02/28/why-brainchip-endeavour-star-and-telix-shares-are-sinking-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7067","BK7040","XJO.AU","BK7016","BK7078","EDV.AU","SGR.AU","BRN.AU","TLX.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":5,"totalSize":200,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/TLX.AU\",params:#limit:5,,,undefined,":[{"date":"2025-02-19","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1739919600000,"name":null,"time":"","dateTimestamp":1739883600000,"actualEps":null},{"date":"2024-08-22","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1724284800000,"name":null,"time":"","dateTimestamp":1724248800000,"actualEps":null},{"date":"2024-02-22","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1708556400000,"name":null,"time":"","dateTimestamp":1708520400000,"actualEps":null},{"date":"2023-10-18","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1697583600000,"name":null,"time":"","dateTimestamp":1697547600000,"actualEps":null},{"date":"2023-08-23","symbol":"TLX.AU","type":"earning","reportTimeType":"","market":"AU","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1692748800000,"name":null,"time":"","dateTimestamp":1692712800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"TLX.AU\",market:\"AU\",,,undefined,":[]}}